SPINE
No increase in adverse events with liposomal bupivacaine vs placebo in elective lumbar spine surgery
Global Spine J. 2019 Apr; 9(2): 133–137.59 patients with degenerative spondylosis scheduled for elective open posterior lumbar decompression and instrumented fusion were randomized to receive a pre-wound closure injection of liposomal bupivacaine (266mg) or placebo for the treatment of post-operative pain. The primary outcome of interest was the incidence of adverse events. The secondary outcome of interest was the length of hospital stay. Results from the study revealed no significant differences in the incidence of adverse events between the liposomal bupivacaine and placebo groups. Similarly, there were no significant differences between the two groups in the length of hospitalization.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
